- Home
- CHRW vs EXAS Comparison
CHRW vs EXAS Comparison
Compare CHRW & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHRW | EXAS |
|---|---|---|
| Founded | 1905 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6B | 19.3B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHRW | EXAS |
|---|---|---|
| Price | $165.39 | $101.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 20 |
| Target Price | ★ $147.47 | $77.94 |
| AVG Volume (30 Days) | 1.5M | ★ 5.2M |
| Earning Date | 01-28-2026 | 11-03-2025 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ 70.68 | N/A |
| EPS | ★ 4.94 | N/A |
| Revenue | ★ $16,504,785,000.00 | $3,082,033,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | $2.97 | $13.51 |
| P/E Ratio | $33.42 | ★ N/A |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $84.68 | $38.81 |
| 52 Week High | $167.90 | $102.66 |
Technical Indicators
Market Signals| Indicator | CHRW | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 66.95 | 84.99 |
| Support Level | $163.87 | $101.45 |
| Resistance Level | $167.90 | $101.88 |
| Average True Range (ATR) | 3.77 | 0.37 |
| MACD | 0.20 | -1.37 |
| Stochastic Oscillator | 81.86 | 59.00 |
Price Performance
Historical ComparisonAbout CHRW C.H. Robinson Worldwide Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 60% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (30%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of transportation management services and a legacy produce-sourcing operation.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.